# Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis

> **NCT00111449** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 600 (—)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00111449
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 600 (—)
- **Last updated:** 2013-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111449, "Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00111449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*